WO2008009856A3 - Modulateurs de hsd17b7 dans le traitement de l'acné ou de l'hyperséborrhée - Google Patents

Modulateurs de hsd17b7 dans le traitement de l'acné ou de l'hyperséborrhée Download PDF

Info

Publication number
WO2008009856A3
WO2008009856A3 PCT/FR2007/051683 FR2007051683W WO2008009856A3 WO 2008009856 A3 WO2008009856 A3 WO 2008009856A3 FR 2007051683 W FR2007051683 W FR 2007051683W WO 2008009856 A3 WO2008009856 A3 WO 2008009856A3
Authority
WO
WIPO (PCT)
Prior art keywords
acne
treatment
hyperseborrhoea
modulators
hsd17b7
Prior art date
Application number
PCT/FR2007/051683
Other languages
English (en)
Other versions
WO2008009856A2 (fr
Inventor
Fernand Labrie
Van Luu-The
Ezequiel L Calvo
Jerome Aubert
Michel Rivier
Sophie Deret
Johannes Voegel
Original Assignee
Galderma Res & Dev
Fernand Labrie
Van Luu-The
Ezequiel L Calvo
Jerome Aubert
Michel Rivier
Sophie Deret
Johannes Voegel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev, Fernand Labrie, Van Luu-The, Ezequiel L Calvo, Jerome Aubert, Michel Rivier, Sophie Deret, Johannes Voegel filed Critical Galderma Res & Dev
Priority to EP07823602A priority Critical patent/EP2046975A2/fr
Priority to CA002656841A priority patent/CA2656841A1/fr
Publication of WO2008009856A2 publication Critical patent/WO2008009856A2/fr
Publication of WO2008009856A3 publication Critical patent/WO2008009856A3/fr
Priority to US12/320,169 priority patent/US20100028879A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/904—Oxidoreductases (1.) acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une méthode in vitro de criblage de composés candidats pour le traitement préventif ou curatif de l'acné, comprenant la détermination de la capacité d'un composé à moduler l'expression ou l'activité de l'hydroxystéroïde (17-beta) deshydrogénase de type 7, ainsi que l'utilisation de modulateurs de l'expression ou de l'activité de cette enzyme pour le traitement de l'acné ou des désordres cutanés associés à une hyperséborrhée. L'invention concerne aussi des méthodes de diagnostic in vitro ou pronostic in vitro de ces pathologies.
PCT/FR2007/051683 2006-07-19 2007-07-18 Modulateurs de hsd17b7 dans le traitement de l'acné ou de l'hyperséborrhée WO2008009856A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07823602A EP2046975A2 (fr) 2006-07-19 2007-07-18 Modulateurs de hsd17b7 dans le traitement de l'acné ou de l'hyperséborrhée
CA002656841A CA2656841A1 (fr) 2006-07-19 2007-07-18 Modulateurs de hsd17b7 dans le traitement de l'acne ou de l'hyperseborrhee
US12/320,169 US20100028879A1 (en) 2006-07-19 2009-01-21 Modulators of HSD17b7 for treating acne or hyperseborrhea

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0653029 2006-07-19
FR0653029A FR2904000A1 (fr) 2006-07-19 2006-07-19 Modulateurs de hsd17b7 dans le traitement de l'acne ou de l'hyperseborrhee

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/320,169 Continuation US20100028879A1 (en) 2006-07-19 2009-01-21 Modulators of HSD17b7 for treating acne or hyperseborrhea

Publications (2)

Publication Number Publication Date
WO2008009856A2 WO2008009856A2 (fr) 2008-01-24
WO2008009856A3 true WO2008009856A3 (fr) 2008-03-06

Family

ID=37708241

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/051683 WO2008009856A2 (fr) 2006-07-19 2007-07-18 Modulateurs de hsd17b7 dans le traitement de l'acné ou de l'hyperséborrhée

Country Status (5)

Country Link
US (1) US20100028879A1 (fr)
EP (1) EP2046975A2 (fr)
CA (1) CA2656841A1 (fr)
FR (1) FR2904000A1 (fr)
WO (1) WO2008009856A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2938335A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de l'isovaleryl-coenzyme a dehydrogenase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
CN110199032A (zh) 2017-01-23 2019-09-03 雷杰纳荣制药公司 羟基类固醇17-β脱氢酶13(HSD17B13)变体及其用途
JP2020516283A (ja) * 2017-04-11 2020-06-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒドロキシステロイド（１７−ベータ）デヒドロゲナーゼ（ｈｓｄ１７ｂ）ファミリーのメンバーのモジュレーターの活性をスクリーニングするためのアッセイ
KR20240125690A (ko) 2017-10-11 2024-08-19 리제너론 파마슈티칼스 인코포레이티드 Pnpla3 i148m 변이를 발현하는 환자의 간 질환의 치료에서의 hsd17b13의 저해
CN112020556A (zh) 2018-03-21 2020-12-01 瑞泽恩制药公司 第13型17β羟基类固醇脱氢酶(HSD17B13)iRNA组成物及其使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032527A2 (fr) * 2003-06-10 2005-04-14 Solvay Pharmaceuticals B.V. Nouveaux composés et leur utilisation en thérapie

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030071B2 (en) * 2005-03-11 2011-10-04 Gargi Seth Restoration of cholesterol independence and its use as a selectable marker in NS0 cell culture

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032527A2 (fr) * 2003-06-10 2005-04-14 Solvay Pharmaceuticals B.V. Nouveaux composés et leur utilisation en thérapie

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LIU H. ET AL.: "Cloning and characterization of human form 2 type 7 17beta-hydroxysteroid dehydrogenase, a primarily 3beta-keto reductase and estrogen activating and androgen inactivating enzyme", J. STEROID BIOCHEM. MOL. BIOL., vol. 94, no. 1-3, February 2005 (2005-02-01), pages 173 - 179, XP004874312, ISSN: 0960-0760 *
LUU-THE V.: "Analysis and characteristics of multiple types of human 17beta-hydroxysteroid dehydrogenase.", J. STEROID BIOCHEM. MOL. BIOL., vol. 76, no. 1-5, January 2001 (2001-01-01), pages 143 - 151, XP002419837 *
OHNESORG T. ET AL.: "Analysis of the 5' flanking regions of human and murine HSD17B7: Identification of a cholesterol dependent enhancer region.", MOL. CELL. ENDOCRINOL., vol. 248, no. 1-2, 27 March 2006 (2006-03-27), pages 164 - 167, XP005335816, ISSN: 0303-7207 *
POIRIER D.: "Inhibitors of 17beta-hydroxysteroid dehydrogenases.", CURR. MED. CHEM., vol. 10, 2003, pages 453 - 477, XP009024878, ISSN: 0929-8673 *

Also Published As

Publication number Publication date
EP2046975A2 (fr) 2009-04-15
US20100028879A1 (en) 2010-02-04
CA2656841A1 (fr) 2008-01-24
WO2008009856A2 (fr) 2008-01-24
FR2904000A1 (fr) 2008-01-25

Similar Documents

Publication Publication Date Title
WO2008083238A3 (fr) Agonistes de récepteur hétérocyclique pour le traitement du diabète et de troubles métaboliques
MY145070A (en) Imidazolothiazole compounds for the treatment of disease
WO2008043087A3 (fr) Composés hétérocycliques azotés bicycliques pour une utilisation en tant qu'inhibiteurs de stéaroyl-coa-désaturase
WO2007127505A3 (fr) Composés chimiques
WO2007137071A3 (fr) Compositions de r(+) et s(-) pramipéxole et procédés d'utilisation de celles-ci
WO2009059150A3 (fr) Biomarqueurs de la stéatose hépatique et procédés les utilisant
MY144970A (en) Heterocyclic compounds
WO2009124330A3 (fr) Traitement de maladies tumorales
WO2010039536A3 (fr) Sirt4 et utilisations de celui-ci
WO2008009856A3 (fr) Modulateurs de hsd17b7 dans le traitement de l'acné ou de l'hyperséborrhée
WO2007123722A3 (fr) Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse
WO2007038264A3 (fr) Methodes associees a gapr-1
WO2008009855A3 (fr) Modulateurs de sc4mol dans le traitement de l'acné ou de l'hyperséborrhée
HK1120830A1 (en) Modulation of 11beta-hydroxysteroid dehydrogenase 1 expression for the treatment of ocular diseases
TW200833688A (en) Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
WO2009066299A3 (fr) Utilisation du génotypage de l'haptoglobine dans le diagnostic et le traitement d'une maladie cardiovasculaire
WO2007101063A3 (fr) Traitement de troubles liés au développement
WO2008009859A3 (fr) Modulateurs de scarb-1 dans le traitement de l'acné ou de l'hyperséborrhée
WO2008009857A3 (fr) Modulateurs de la udp-glucose céramide glucosyltransférase dans le traitement de l'acné ou de l'hyperkératinisation
WO2008009854A3 (fr) Modulateurs du transporteur abcd3 dans le traitement de l'acné ou de l'hyperséborrhée
WO2008009858A3 (fr) Modulateurs de elovl5 dans le traitement de l'acné ou de l'hyperséborrhée
WO2008140708A8 (fr) Utilisation d'inhibiteurs de hdac pour traiter des troubles du rythme cardiaque
WO2008009852A3 (fr) Modulateurs de la lanostérol synthétase dans le traitement de l'acné ou de l'hyperséborrhée
WO2008070552A3 (fr) Inhibiteurs de la protéine tyrosine phosphatase permettant de favoriser l'hypertrophie cardiaque physiologique
WO2007139970A3 (fr) Gène men1 pour le diagnostic et le traitement du diabète

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07823602

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007823602

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2656841

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU